05
Dec
- 505(b)(2) NDA resubmission is expected in mid-2017
December 5, 2016
SAN DIEGO, Dec. 5, 2016 /PRNewswire/ -- SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") today announced that its pivotal study...